The enhancing effects of obesity on mammary tumor growth and Akt/mTOR pathway activation persist after weight loss and are reversed by RAD001

Rebecca E. De Angel, Claudio J. Conti, Karrie E. Wheatley, Andrew Brenner, Glen Otto, Linda A. deGraffenried, Stephen D. Hursting

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

The prevalence of obesity, an established risk and progression factor for postmenopausal breast cancer, remains high in US women. Activation of Akt/mammalian target of rapamycin (mTOR) signaling plays a key role in the obesity-breast cancer link. However, the impact of weight normalization in obese postmenopausal women on breast tumorigenesis and/or Akt/mTOR activation is poorly characterized. To model this, ovariectomized female C57BL/6 mice were fed a control diet (n=20), a calorie restriction (CR) regimen (n=20), or a diet-induced obesity (DIO) diet (n=30). At week 17, DIO mice were switched to control diet, resulting in formerly obese (FOb) mice with weights identical to the controls by week 20. MMTV-Wnt-1 mammary tumor cells were injected at 20wk into each mouse. Two weeks post-injection, vehicle or the mTOR inhibitor RAD001 at 10 or 15mg/kg body weight (n=10/diet group) was administered by gavage twice/week until termination. Relative to controls, CR mice had decreased (and DIO mice had increased) serum insulin-like growth factor-1 (IGF-1) and phosphorylation of Akt/mTOR pathway components. RAD001 decreased tumor growth in the CR, control, and FOb mice. Wnt-1 tumor cells treated in vitro with serum from mice from each group established that diet-dependent circulating factors contribute to tumor growth and invasiveness. These findings suggest weight normalization in obese mice does not immediately reverse tumor progression or Akt/mTOR activation. Treatment with RAD001 blocked mammary tumor development and mTOR activation observed in the FOb mice, suggesting combination of lifestyle and pharmacologic strategies may be effective for breaking the obesity-breast cancer link.

Original languageEnglish (US)
Pages (from-to)446-458
Number of pages13
JournalMolecular Carcinogenesis
Volume52
Issue number6
DOIs
StatePublished - Jun 2013

Fingerprint

Sirolimus
Weight Loss
Obesity
Breast Neoplasms
Diet
Obese Mice
Growth
Weights and Measures
Neoplasms
Everolimus
Somatomedins
Serum
Inbred C57BL Mouse
Life Style
Carcinogenesis
Breast
Body Weight
Phosphorylation
Injections

Keywords

  • Adiposity
  • Breast cancer
  • Energy balance
  • Weight loss
  • Wnt-1

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Biology

Cite this

The enhancing effects of obesity on mammary tumor growth and Akt/mTOR pathway activation persist after weight loss and are reversed by RAD001. / De Angel, Rebecca E.; Conti, Claudio J.; Wheatley, Karrie E.; Brenner, Andrew; Otto, Glen; deGraffenried, Linda A.; Hursting, Stephen D.

In: Molecular Carcinogenesis, Vol. 52, No. 6, 06.2013, p. 446-458.

Research output: Contribution to journalArticle

De Angel, Rebecca E. ; Conti, Claudio J. ; Wheatley, Karrie E. ; Brenner, Andrew ; Otto, Glen ; deGraffenried, Linda A. ; Hursting, Stephen D. / The enhancing effects of obesity on mammary tumor growth and Akt/mTOR pathway activation persist after weight loss and are reversed by RAD001. In: Molecular Carcinogenesis. 2013 ; Vol. 52, No. 6. pp. 446-458.
@article{69eb9bc27ad041a3b2e461726754035b,
title = "The enhancing effects of obesity on mammary tumor growth and Akt/mTOR pathway activation persist after weight loss and are reversed by RAD001",
abstract = "The prevalence of obesity, an established risk and progression factor for postmenopausal breast cancer, remains high in US women. Activation of Akt/mammalian target of rapamycin (mTOR) signaling plays a key role in the obesity-breast cancer link. However, the impact of weight normalization in obese postmenopausal women on breast tumorigenesis and/or Akt/mTOR activation is poorly characterized. To model this, ovariectomized female C57BL/6 mice were fed a control diet (n=20), a calorie restriction (CR) regimen (n=20), or a diet-induced obesity (DIO) diet (n=30). At week 17, DIO mice were switched to control diet, resulting in formerly obese (FOb) mice with weights identical to the controls by week 20. MMTV-Wnt-1 mammary tumor cells were injected at 20wk into each mouse. Two weeks post-injection, vehicle or the mTOR inhibitor RAD001 at 10 or 15mg/kg body weight (n=10/diet group) was administered by gavage twice/week until termination. Relative to controls, CR mice had decreased (and DIO mice had increased) serum insulin-like growth factor-1 (IGF-1) and phosphorylation of Akt/mTOR pathway components. RAD001 decreased tumor growth in the CR, control, and FOb mice. Wnt-1 tumor cells treated in vitro with serum from mice from each group established that diet-dependent circulating factors contribute to tumor growth and invasiveness. These findings suggest weight normalization in obese mice does not immediately reverse tumor progression or Akt/mTOR activation. Treatment with RAD001 blocked mammary tumor development and mTOR activation observed in the FOb mice, suggesting combination of lifestyle and pharmacologic strategies may be effective for breaking the obesity-breast cancer link.",
keywords = "Adiposity, Breast cancer, Energy balance, Weight loss, Wnt-1",
author = "{De Angel}, {Rebecca E.} and Conti, {Claudio J.} and Wheatley, {Karrie E.} and Andrew Brenner and Glen Otto and deGraffenried, {Linda A.} and Hursting, {Stephen D.}",
year = "2013",
month = "6",
doi = "10.1002/mc.21878",
language = "English (US)",
volume = "52",
pages = "446--458",
journal = "Molecular Carcinogenesis",
issn = "0899-1987",
publisher = "Wiley-Liss Inc.",
number = "6",

}

TY - JOUR

T1 - The enhancing effects of obesity on mammary tumor growth and Akt/mTOR pathway activation persist after weight loss and are reversed by RAD001

AU - De Angel, Rebecca E.

AU - Conti, Claudio J.

AU - Wheatley, Karrie E.

AU - Brenner, Andrew

AU - Otto, Glen

AU - deGraffenried, Linda A.

AU - Hursting, Stephen D.

PY - 2013/6

Y1 - 2013/6

N2 - The prevalence of obesity, an established risk and progression factor for postmenopausal breast cancer, remains high in US women. Activation of Akt/mammalian target of rapamycin (mTOR) signaling plays a key role in the obesity-breast cancer link. However, the impact of weight normalization in obese postmenopausal women on breast tumorigenesis and/or Akt/mTOR activation is poorly characterized. To model this, ovariectomized female C57BL/6 mice were fed a control diet (n=20), a calorie restriction (CR) regimen (n=20), or a diet-induced obesity (DIO) diet (n=30). At week 17, DIO mice were switched to control diet, resulting in formerly obese (FOb) mice with weights identical to the controls by week 20. MMTV-Wnt-1 mammary tumor cells were injected at 20wk into each mouse. Two weeks post-injection, vehicle or the mTOR inhibitor RAD001 at 10 or 15mg/kg body weight (n=10/diet group) was administered by gavage twice/week until termination. Relative to controls, CR mice had decreased (and DIO mice had increased) serum insulin-like growth factor-1 (IGF-1) and phosphorylation of Akt/mTOR pathway components. RAD001 decreased tumor growth in the CR, control, and FOb mice. Wnt-1 tumor cells treated in vitro with serum from mice from each group established that diet-dependent circulating factors contribute to tumor growth and invasiveness. These findings suggest weight normalization in obese mice does not immediately reverse tumor progression or Akt/mTOR activation. Treatment with RAD001 blocked mammary tumor development and mTOR activation observed in the FOb mice, suggesting combination of lifestyle and pharmacologic strategies may be effective for breaking the obesity-breast cancer link.

AB - The prevalence of obesity, an established risk and progression factor for postmenopausal breast cancer, remains high in US women. Activation of Akt/mammalian target of rapamycin (mTOR) signaling plays a key role in the obesity-breast cancer link. However, the impact of weight normalization in obese postmenopausal women on breast tumorigenesis and/or Akt/mTOR activation is poorly characterized. To model this, ovariectomized female C57BL/6 mice were fed a control diet (n=20), a calorie restriction (CR) regimen (n=20), or a diet-induced obesity (DIO) diet (n=30). At week 17, DIO mice were switched to control diet, resulting in formerly obese (FOb) mice with weights identical to the controls by week 20. MMTV-Wnt-1 mammary tumor cells were injected at 20wk into each mouse. Two weeks post-injection, vehicle or the mTOR inhibitor RAD001 at 10 or 15mg/kg body weight (n=10/diet group) was administered by gavage twice/week until termination. Relative to controls, CR mice had decreased (and DIO mice had increased) serum insulin-like growth factor-1 (IGF-1) and phosphorylation of Akt/mTOR pathway components. RAD001 decreased tumor growth in the CR, control, and FOb mice. Wnt-1 tumor cells treated in vitro with serum from mice from each group established that diet-dependent circulating factors contribute to tumor growth and invasiveness. These findings suggest weight normalization in obese mice does not immediately reverse tumor progression or Akt/mTOR activation. Treatment with RAD001 blocked mammary tumor development and mTOR activation observed in the FOb mice, suggesting combination of lifestyle and pharmacologic strategies may be effective for breaking the obesity-breast cancer link.

KW - Adiposity

KW - Breast cancer

KW - Energy balance

KW - Weight loss

KW - Wnt-1

UR - http://www.scopus.com/inward/record.url?scp=84876438500&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876438500&partnerID=8YFLogxK

U2 - 10.1002/mc.21878

DO - 10.1002/mc.21878

M3 - Article

C2 - 22290600

AN - SCOPUS:84876438500

VL - 52

SP - 446

EP - 458

JO - Molecular Carcinogenesis

JF - Molecular Carcinogenesis

SN - 0899-1987

IS - 6

ER -